Evidence map›Paper›PMID 15599394›Full record

ReviewThe Journal of clinical investigation2004

TB, or not TB: that is the question -- does TLR signaling hold the answer?

Terence M Doherty, Moshe Arditi

Abstract readCommentReview
In one paragraph

Review in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Mycobacterial signaling through toll-like receptors.Frontiers in cellular and infection microbiology · 2012
    Review
  13. Article
  14. Tuberculosis immunity: opportunities from studies with cattle.Clinical & developmental immunology · 2011
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Terence M DohertyAtherosclerosis Research Center, Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Moshe Arditi

Funding

MOLECULAR PATHOGENESIS OF CHLAMYDIA-INDUCED ATHEROGENESIR01HL066436 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI ARDITI, MOSHE · 2001 to 2013
$3.6M
MD2 signaling in LPS/TLR4 induced cellular responsesR01AI058128 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI ARDITI, MOSHE · 2004 to 2009
$2.4M
NHLBI NIH HHS HL 66436NHLBI NIH HHS R01 HL066436NIAID NIH HHS AI 058128NIAID NIH HHS R01 AI058128
6 · The paper itself

Abstract

Innate immunity critically depends on signaling by Toll-like receptors (TLRs) that rely heavily on an intracellular adapter protein called myeloid differentiation factor 88 (MyD88). Adaptive immune defenses are generally thought to be orchestrated by innate immune responses and so should require intact TLR-MyD88 signaling pathways. But a surprising new study in MyD88-null mice infected with Mycobacterium tuberculosis challenges this view and instead suggests that MyD88 may not be absolutely required for a normal adaptive immune response.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntigens, DifferentiationBacterial InfectionsHumansMembrane GlycoproteinsMiceModels, BiologicalMycobacterium tuberculosisMyeloid Differentiation Factor 88PhagosomesProtein ConformationReceptors, Cell SurfaceReceptors, ImmunologicSignal TransductionToll-Like ReceptorsAdaptor Proteins, Signal TransducingAntigens, DifferentiationMembrane GlycoproteinsMYD88 protein, humanMyd88 protein, mouseMyeloid Differentiation Factor 88Receptors, Cell SurfaceReceptors, ImmunologicToll-Like Receptors

Identifiers

PMID15599394
PMCPMC535076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.